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a  b  s  t  r  a  c  t
The  abrupt  discontinuation  of  prolonged  benzodiazepine  treatment  elicits  a withdrawal  syndrome  with
increased  anxiety  as a major  symptom.  The  neural  mechanisms  underlying  benzodiazepine  physical
dependence  are  still  insufﬁciently  understood.  Flumazenil,  the  non-selective  antagonist  of  the  benzodi-
azepine  binding  site  of  GABAA receptors  was  capable  of  preventing  and  reversing  the  increased  anxiety
during  benzodiazepine  withdrawal  in  animals  and  humans  in  some,  but  not all  studies.  On  the  other
hand,  a  number  of  data  suggest  that GABAA receptors  containing  1 subunits  are  critically  involved  in
processes  developing  during  prolonged  use of  benzodiazepines,  such  are  tolerance  to sedative  effects,
liability to physical  dependence  and  addiction.  Hence,  we  investigated  in the  elevated  plus  maze  the  level
of anxiety  24 h  following  21  days  of diazepam  treatment  and  the  inﬂuence  of ﬂumazenil  or  a  preferen-
tial  1-subunit  selective  antagonist  CCt  on  diazepam  withdrawal  syndrome  in  rats.  Abrupt  cessation
of  protracted  once-daily  intraperitoneal  administration  of  2 mg/kg  diazepam  induced  a withdrawal  syn-
drome,  measured  by  increased  anxiety-like  behavior  in  the  elevated  plus  maze  24 h after  treatment
cessation.  Acute  challenge  with  either  ﬂumazenil  (10  mg/kg)  or  CCt (1.25,  5  and  20 mg/kg)  alleviated  the
diazepam  withdrawal-induced  anxiety.  Moreover,  both  antagonists  induced  an  anxiolytic-like  response
close,  though  not  identical,  to that  seen  with  acute  administration  of  diazepam.  These ﬁndings  imply that
the mechanism  by  which  antagonism  at  GABAA receptors  may  reverse  the  withdrawal-induced  anxiety
involves  the  1 subunit  and  prompt  further  studies  aimed  at  linking  the  changes  in behavior  with  possible
adaptive  changes  in subunit  expression  and  function  of GABAA receptors.. Introduction
Benzodiazepines are reasonably safe and effective drugs in
hort-term treatment of different psychiatric and neurologi-
al disorders (anxiety, sleep disturbances, muscle spasms and
eizure disorders). However, their protracted use remains debat-
ble because it is associated with development of tolerance to
ome of their effects, liability for physical dependence and abuse
otential. Abrupt cessation of prolonged benzodiazepine treat-
ent is followed by a withdrawal syndrome, the main indicator of
hysical dependence. Benzodiazepine withdrawal has been char-
cterized by many signs (e.g., anxiety, insomnia and in more severe
ases seizures) that are opposite to their expected therapeutic
ffects. Despite the half-century long clinical and experimental
xperience, the molecular and neurobiological mechanisms under-
ying the development of benzodiazepine dependence are still
∗ Corresponding author. Tel.: +381 11 3951280; fax: +381 11 3972840.
E-mail address: miroslav@pharmacy.bg.ac.rs (M.M.  Savic´).
361-9230/$ – see front matter ©  2012 Elsevier Inc. All rights reserved.
ttp://dx.doi.org/10.1016/j.brainresbull.2012.10.011© 2012 Elsevier Inc. All rights reserved.
insufﬁciently understood (Dell’osso and Lader, 2012; Licata and
Rowlett, 2008).
Non-selective benzodiazepines, such as diazepam, bind to
GABAA receptors containing 1, 2, 3 or 5 subunits in addition to
the 2 subunit and allosterically modulate their activity. Therefore,
it could be expected that alterations in GABAA receptor function
provide possible mechanisms for the development of tolerance
and physical dependence (reviewed in Bateson, 2002). A number
of in vitro and ex vivo studies have suggested that abrupt with-
drawal from the prolonged exposure to benzodiazepines results in
expression changes of distinct GABAA receptor subunits (reviewed
in Uusi-Oukari and Korpi, 2010). These changes could be associated
with a decrease of postsynaptic GABA sensitivity (Gallager et al.,
1984), or “functional uncoupling” between the recognition sites
of benzodiazepines and GABA (Ali and Olsen, 2001; Hu and Ticku,
1994). More recently, it has been proposed that GABAA receptors
containing 1 subunits (1GABAA receptors) are critically involved
in processes that underlie tolerance to the sedative effect, lia-
bility to physical dependence and addiction (Mirza and Nielsen,
2006; Tan et al., 2010; van Rijnsoever et al., 2004). However, the
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F AD, ac
s
p
e
G
t
(
b
i
t
N
p
ﬂ
a
(
2
l
i
a
t
r
b
m
s
o
R
d
p
o
(
o
r
a
t
n
(
w
o
aig. 1. The schematic presentation of experimental design and statistical analysis. 
olvent;  DZP, diazepam; EXP, experiment.
henomena such as withdrawal and dependence liability are hardly
xplainable on the basis of the neuronal adaptations at the level of
ABAA receptors only, and involvement of other neurotransmit-
ers, such as glutamate and dopamine, has been also implicated
Allison and Pratt, 2003; Diaz et al., 2011).
Flumazenil is a non-selective antagonist of the benzodiazepine
inding site of GABAA receptors. In previous studies, the admin-
stration of ﬂumazenil after prolonged benzodiazepine treatment
ended to exert an ambiguous inﬂuence on the anxiety level.
amely, while some experiments showed that ﬂumazenil can
recipitate withdrawal symptoms, there was also evidence that
umazenil is capable of preventing and reversing the increased
nxiety during benzodiazepine withdrawal in animals and humans
File and Hitchcott, 1990; Hood et al., 2009; Licata and Rowlett,
008). File and Hitchcott (1990) have proposed that the anxiety
evel of the subject determines the direction of the ﬂumazenil’s
nﬂuence on anxiety: when this is high, such as during benzodi-
zepine withdrawal, ﬂumazenil would become anxiolytic; when
his is low, ﬂumazenil would increase anxiety. However, the
eceptor mechanism by which ﬂumazenil affects anxiety during
enzodiazepine withdrawal is still not established.
In laboratory animals, physical dependence to benzodiazepines
ay  be observed as the emergence of characteristic symptoms,
uch as withdrawal anxiety, 12, 24 or 48 h upon abrupt cessation
f the prolonged treatment (dos Santos et al., 2010; Licata and
owlett, 2008). An anxiogenic response to benzodiazepine with-
rawal in rodents is most commonly assessed using the elevated
lus maze (EPM), and quantiﬁed by a decrease in the percentage
f open arm entries and the percentage of time spent in open arms
dos Santos et al., 2010; File et al., 1987). Based on the proposed role
f 1-containing GABAA receptors in alterations in GABA-ergic neu-
otransmission following prolonged exposure to benzodiazepines,
nd also the observed bidirectional effects of ﬂumazenil, it is worth
o investigate in parallel the inﬂuence of a non-selective antago-
ist (ﬂumazenil) and a preferential 1-subunit selective antagonist
CCt) on diazepam withdrawal syndrome. In the present study,
e assessed in the EPM the level of anxiety 24 h following 21 days
f diazepam treatment and examined the inﬂuence of ﬂumazenil
nd CCt on rat behavior during diazepam withdrawal. The dosesute administration of diazepam; WD,  diazepam withdrawal; FLU, ﬂumazenil; SOL,
of antagonists were chosen in accordance with our previous stud-
ies, which demonstrated that ﬂumazenil applied in doses up to
20 mg/kg and CCt applied in doses up to 30 mg/kg were behav-
iorally inactive on their own in the EPM test (Savic´ et al., 2004).
2. Materials and methods
2.1. Animals
Experiments were carried out on 74 male Wistar rats (Military Farm, Belgrade,
Serbia), weighing 180–200 g at the beginning of experiments. All procedures in the
study conformed to EEC Directive 86/609 and were approved by the Ethical Com-
mittee on Animal Experimentation of the Faculty of Pharmacy in Belgrade. The rats
were group-housed (six per cage) in transparent plastic cages with tap water and
food pellets available ad libitum and kept in standard laboratory conditions. The
temperature of the animal room was 22 ± 1 ◦C, the relative humidity 40–70%, the
illumination 120 lx, and 12/12 h light/dark period (light on at 6:00 h). All handling,
daily administration of treatment and testing took place during the light period of
the cycle, between 9:00 and 13:00 h.
2.2. Drugs
The compounds used in this study were diazepam (Galenika, Serbia), the non-
selective GABAA antagonist ﬂumazenil (Feicheng BoYuan Fine Chemicals Co., Ltd,
China) and the preferential 1-subunit afﬁnity selective GABAA antagonist CCt
(t-butyl--carboline-3-carboxylate), synthesized at the Department of Chemistry
and Biochemistry, University of Wisconsin-Milwaukee, USA. The compounds were
dissolved/suspended in a solvent containing 85% distilled water, 14% propylene gly-
col,  and 1% Tween-80 and were administered intraperitoneally (IP) in a volume of
1  ml/kg.
2.3. Experimental procedure
Two  separate experiments were performed, as illustrated in Fig. 1. In Experi-
ment 1, the rats were randomly divided into four pre-treatment groups: two groups
were repeatedly treated once daily with diazepam (2 mg/kg/day) and the other two
groups received solvent IP, during 21 days. On the testing day (22nd day), 24 h after
the last pre-treatment injection, the animals repeatedly treated with diazepam were
acutely challenged with ﬂumazenil 10 mg/kg or did not receive any treatment. The
rats repeatedly treated with solvent during 21 days, received 2 mg/kg diazepam or
did not receive any treatment on the testing day.
In Experiment 2, another set of experimentally naïve animals was randomly dis-
tributed among six pre-treatment groups: four groups were repeatedly treated once
daily with diazepam (2 mg/kg/day), and the other two  groups received treatment
with solvent during 21 days. On the testing day, 24 h after the last pre-treatment
injection, animals repeatedly treated with diazepam were acutely challenged with
either solvent or CCt at a dose of 1.25 mg/kg, 5 mg/kg or 20 mg/kg. On the other
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Table  1
The effects of diazepam withdrawal on behavior in the EPM and the accompanying two-way ANOVAs with treatment groups and experimental conditions as factors. Treatment
groups were control (SOL) and diazepam-withdrawn (WD) groups, whereas experimental conditions were Experiment 1 and Experiment 2. Data are mean ± SEM; number
of  animals per treatment group was 6–8.
Parameter Experiment 1 Experiment 2 Two-way ANOVA
SOL WD SOL WD Treatment
group (SOL
vs. WD)
Experimental
condition
(Experiment 1 vs.
Experiment 2)
Interaction
F(1,25) P F(1,25) P F(1,25) P
% open time 43.50 ± 3.34 28.86 ± 6.48 46.67 ± 8.16 31.25 ± 6.70 5.85 0.023 0.20 0.659 0.01 0.951
%  open entries 41.63 ± 2.58 33.71 ± 4.47 37.00 ± 5.20 34.25 ± 3.56 1.86 0.085 0.27 0.606 0.44 0.516
Time  in distal part of open arms (s) 36.49 ± 3.24 20.67 ± 8.00 38.43 ± 8.75 24.60 ± 8.26 4.18 0.052 0.16 0.689 0.02 0.899
Risk  assessment behavior (s) 33.50 ± 6.70 49.91 ± 7.43 39.78 ± 13.70 62.05 ± 12.61 3.45 0.075 0.78 0.385 0.08 0.781
± 0.6
 ± 0.8
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pTotal  distance traveled (m) 10.31 ± 0.86 9.56 ± 0.51 9.65
Total  entries 12.88 ± 0.95 11.43 ± 0.43 11.50
Closed entries 7.50 ± 0.63 7.57 ± 0.57 7.17
and, the animals repeatedly treated with solvent received either 2 mg/kg diazepam
r solvent as a treatment.
.4. Behavior in the EPM
The EPM apparatus was constructed of sheet metal, with a black rubber ﬂoor.
t  consisted of two opposed open arms (50 cm × 10 cm) with ledges (0.3 cm high)
nd two  opposed enclosed arms (50 cm × 10 cm × 40 cm), connected by the junc-
ion area (10 cm ×10 cm). The whole apparatus was elevated 50 cm above the ﬂoor.
llumination in the experimental room was  provided with one red neon tube ﬁxed
n  the ceiling above the maze. Light intensity was 10 lx on the surface of the closed
rms. Twenty minutes after administration of the appropriate treatment on the test-
ng day, single rats were placed in the center of the maze, facing one of the enclosed
rms and were allowed to freely explore the apparatus during 5 min. The standard
patiotemporal variables were recorded and analyzed using the ANY-maze Video
racking System software (Stoelting Co., Wood Dale, IL, USA) in accordance with
ur previous studies (Savic´ et al., 2004, 2010). The primary indices of anxiety were
he  percentage of open arm entries, the percentage of time spent on the open arms
nd time spent in the distal parts of the open arms. The parameters closely related
o  motor activity were the total distance traveled, number of total entries and closed
rm  entries. An entry into an open arm, closed arm, or the distal part of the open arm
as  scored when 90% of animal crossed the virtual line separating the neighboring
ones, whereas an exit occurred when more than 90% of animal left the respective
one. The distal part of open arms was deﬁned as the area of the most distant 30% of
pen arms. Additionally, time spent in risk assessment behavior, deﬁned as exiting
 closed arm with forepaws and head only, and investigating the surroundings, was
cored by an observer blind to treatment assignments. The risk assessment behav-
or represents a behavioral dimension closely related to certain aspects of anxiety
avoidance of danger, decision making and approach/avoid conﬂict) (Cruz et al.,
994; Rodgers and Johnson, 1995).
.5. Statistical analysis
All numerical data presented in the ﬁgures were given as the mean ± SEM. In
rder to validate the experimental model of withdrawal-induced anxiety in our lab-
ratory settings, a two-way ANOVA with treatment (withdrawal groups and control
roups) and experimental condition (Experiment 1 and Experiment 2) as factors
ere applied. The effects of the antagonists, ﬂumazenil and CCt, on diazepam
ithdrawal-induced anxiety were analyzed by two  separate one-way ANOVAs, in
hich withdrawal groups (WD) and acute diazepam groups (AD) served as reference
roups for anxiogenic and anxiolytic response, respectively. Groups included in each
tatistical analysis were depicted in Fig. 1. If the ANOVA was  signiﬁcant (P < 0.05),
ost  hoc Student–Newman–Keuls test (SNK’s test) was  performed. The animals that
ell  from the EPM were excluded from data analysis. Statistical analyses were per-
ormed with ANY-maze software, where applicable, while SigmaPlot 11.0 (Systat
oftware Inc., Richmond, CA, USA) was used elsewhere.
. Results
.1. The effects of diazepam withdrawal on behavior in the EPM
Table 1 shows the effects of diazepam withdrawal on the
nxiety-related and motor activity-related parameters in the EPM.
he two-way ANOVA, with treatment group and experimental con-
ition as factors, revealed signiﬁcant effect of treatment on the
ercentage of open time (P = 0.023). At the same time, decrease in5 9.26 ± 0.52 0.71 0.407 0.51 0.480 0.07 0.781
5 10.88 ± 0.72 1.75 0.197 1.52 0.228 0.28 0.604
0 7.25 ± 0.80 0.01 0.910 0.23 0.633 0.01 0.933
percentage of open arm entries and the time spent in the distal parts
of the open arms for groups withdrawn from diazepam compared
to control groups was  close to signiﬁcant (P = 0.085 and P = 0.052,
respectively). Time spent in risk assessment behavior tended to be
greater in groups withdrawn from diazepam (P = 0.075). The inﬂu-
ence of treatment on the motor activity-related parameters (total
distance traveled, total entries and closed arm entries) was  not sta-
tistically signiﬁcant. Neither experimental condition as factor nor
interactions between factors were statistically signiﬁcant.
3.2. Experiment 1
In regard to percentage of open time, the analysis showed a sig-
niﬁcant main effect of factor treatment (F(2,18) = 13.34, P < 0.001).
Post hoc SNK’s test revealed that the percentage of open time was
increased for groups WD + FLU and AD, in comparison with WD
group (P = 0.003 and P < 0.001, respectively), as shown in Fig. 2A.
The one-way ANOVA also revealed a signiﬁcant main effect of
treatment on the percentage of open arm entries (F(2,18) = 6.38,
P = 0.008). Animals from WD + FLU and AD groups showed signif-
icantly higher percentage of open arm entries than animals from
WD group (P = 0.028 and P = 0.007, respectively), as shown in Fig. 2B.
The inﬂuence of treatment on the time spent in the distal part
of open arms was nearly signiﬁcant (F(2,18) = 3,47, P = 0.053) and
post hoc SNK’s test showed a signiﬁcant difference between ani-
mals from AD and WD group (P = 0.018; Fig. 2C). Overall, there
was a signiﬁcant effect of treatment on the time spent in risk
assessment behavior (F(2,18) = 12.48, P < 0.001). Post hoc compari-
son revealed a signiﬁcant decrease in this parameter for WD + FLU
and AD groups compared to WD group (P = 0.012 and P < 0.001,
respectively). Moreover, animals from WD + FLU group spent signif-
icantly more time in risk assessment behavior than animals from
AD group (P = 0.042; Fig. 2D). In regard to motor activity-related
parameters, one-way ANOVA did not reveal a signiﬁcant inﬂuence
of treatment on the total distance traveled (F(2,18) = 0.32, P = 0.729)
(data not shown) and total entries (F(2,18) = 0.16, P = 0.857) (Fig. 2B).
However, the inﬂuence of treatment on closed arm entries was sig-
niﬁcant, according to one-way ANOVA (F(2,18) = 4.84, P = 0.021). Post
hoc test revealed that animals from AD group exerted signiﬁcantly
fewer closed arm entries compared to animals from WD group
(P = 0.018); this parameter could be observed in the Fig. 2B, as dif-
ferences in total entries (gray bars) and open arm entries (hatched
bars).3.3. Experiment 2
Considering the percentage of open time, the one-way ANOVA
demonstrated a signiﬁcant inﬂuence of treatment (F(4,34) = 5.01,
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Fig. 2. The effects of diazepam withdrawal (WD), administration of 10 mg/kg ﬂumazenil to diazepam withdrawn animals (WD  + FLU) and acute administration of diazepam
(AD)  on the anxiety-related parameters. Graphs A, C and D represent the inﬂuence of treatment on the percentage of open time, the time spent in the distal parts of open
arms  and the time spent in risk assessment behavior, respectively. Graph B shows the effects of treatment on the percentage of open arm entries, indicated as the ratio of
open  arm entries (hatched bars) and total entries (open gray bars). *P < 0.05, **P < 0.01, and ***P < 0.001 compared to the diazepam-withdrawn group (WD  group); †P < 0.05
compared to the acute diazepam group (AD group). The number of animals per treatment group was 7.
Fig. 3. The effects of diazepam withdrawal (WD), administration of 1.25 mg/kg, 5 mg/kg or 20 mg/kg CCt to the diazepam withdrawn animals (WD  + CCt 1.25, WD + CCt
5  and WD + CCt 20) and acute administration of diazepam (AD) on the anxiety-related parameters. Graphs A, C and D represent the effects of treatment on the percentage
of  open time, the time spent in the distal parts of open arms and the time spent in risk assessment behavior. Graph B presents the effects of treatment on the percentage of
open  arm entries, indicated as the ratio of open arm entries (hatched bars) and total entries (open gray bars). *P < 0.05, **P < 0.01 and ***P < 0.001 compared to the diazepam-
withdrawn group (WD  group); †P < 0.05 and ††P < 0.01 compared to the acute diazepam group (AD group). The number of animals per treatment groups was  8, 7, 9, 8 and 7,
for  WD,  WD + CCt 1.25, WD + CCt 5, WD + CCt 20 and AD group, respectively.
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 = 0.003). Post hoc test showed that for all the three groups with-
rawn from diazepam and challenged with CCt (WD  + 1.25 CCt,
D + 5 CCt and WD + 20 CCt), as well as for AD group, the
ercentage of open time was increased compared to WD group
P = 0.032, P = 0.031, P = 0.014 and P = 0.001, respectively; Fig. 3A).
he inﬂuence of treatment on the percentage of open arm entries
as also signiﬁcant (F(4,34) = 6.88, P < 0.001). SNK’s test revealed that
roups WD + 5 CCt, WD + 20 CCt and AD showed signiﬁcantly
igher percentage of open arm entries compared to WD group
P = 0.049, P = 0.021 and P < 0.001, respectively). Simultaneously, the
ercentage of open arm entries was lower for all the three groups
hallenged with CCt (WD  + 1.25 CCt, WD + 5 CCt and WD + 20
CCt) compared to AD group (P = 0.007, P = 0.03 and P = 0.046,
espectively), as presented in Fig. 3B. The inﬂuence of treatment
n the time spent in the distal part of open arms was  signiﬁcant
F(4,34) = 3.53, P = 0.016) and the AD group was different compared
o WD group (P = 0.009; Fig. 3C). In regard to the time spent in risk
ssessment behavior, there was also a signiﬁcant effect of treat-
ent (F(4,34) = 2.88, P = 0.037). Animals from the groups WD + 1.25
CCt and WD + 5 CCt tended to have the decreased time spent in
isk assessment behavior in comparison with WD group (P = 0.067
nd P = 0.072, respectively), while decreases of this parameter
eached statistical signiﬁcance for the groups WD + 20 CCt and
D (P = 0.028 and P = 0.029 in comparison with WD group, respec-
ively; shown in Fig. 3D). There was no inﬂuence of treatment on
he analyzed motor activity-related parameters, namely total dis-
ance traveled (F(4,34) = 0.76, P = 0.561), total entries (F(4,34) = 1,18,
 = 0.335) and closed arm entries (F(4,34) = 2.02, P = 0.113) (data not
hown).
. Discussion
The withdrawal syndrome that occurs after abrupt discontinua-
ion of chronic drug use is usually characterized by the emergence
f a negative emotional state involving anxiety (Koob and Volkow,
010). The EPM is a valuable animal model to study anxiety-
ike behavior that occurs during benzodiazepine withdrawal in
odents (File and Hitchcott, 1990). Using this paradigm, File and
ndrews (1991) showed that repeated IP administration of 2 mg/kg
iazepam, once daily during 21 days, could induce an anxiogenic
esponse, measured 24 h after the last dose of diazepam. In the
resent study, the similar pattern of anxiety-like responses in rats
fter diazepam withdrawal was observed in both experiments.
ncreased anxiety was indicated by the decrease in open arm explo-
ation and nearly signiﬁcant increase in the time spent in risk
ssessment behavior.
In order to validate the experimental model of withdrawal-
nduced anxiety, we opted to use a proper vehicle control in
ne, but not in the other experiment (Experiment 2 vs. Experi-
ent 1). Namely, it is known that intraperitoneal saline injection
n rodents affects core temperature and heart rate, indicating
n acute stress response (Dilsaver and Majchrzak, 1990; Meijer
t al., 2006), which may  bias the outcome in an anxiety test.
owever, subtle differences between two experimental designs
id not inﬂuence the animals’ behavior in our study, as there
ere no signiﬁcant differences for factor experimental condition
n the two-way ANOVA analysis for any of the observed parame-
ers.
It has been postulated that benzodiazepine withdrawal affects
everal neuronal circuits. A close interrelationship between glu-
amatergic, dopaminergic and GABAergic neurons in key brain
egions involved in the development of dependence and expression
f anxiety is exempliﬁed by ﬁndings that activation of 1GABAA
eceptors triggers synaptic plasticity in the mesolimbic dopamine
athway and mediates inhibition of glutamatergic projectionarch Bulletin 91 (2013) 1– 7 5
neurons in basolateral amygdala (Heikkinen et al., 2009; McDonald
and Mascagni, 2004; Tan et al., 2010). Moreover, withdrawal after
protracted benzodiazepine treatment leads to down-regulation of
1GABAA receptors and functional uncoupling between GABA- and
benzodiazepine- binding sites (Hu and Ticku, 1994; Tietz et al.,
1999). These data suggest that prolonged diazepam treatment and
subsequent withdrawal may  modulate neuronal circuits by adap-
tations at 1GABAA receptors. A major role of these receptors in
processes underlying dependence liability has been supported by
ﬁndings from pharmacological studies. Namely, SL651498, L-838,
417 and TPA 023, the compounds which bind to and modulate the
benzodiazepine-sensitive GABAA receptors, but are devoid of efﬁ-
cacy at the 1 subtype, are less prone to induce dependency (Ator
et al., 2010; Griebel et al., 2003).
The results from Experiment 1 are in agreement with the ﬁnding
that ﬂumazenil is able to reverse the anxiety induced by withdrawal
of diazepam in rats (File and Hitchcott, 1990). In the present study,
acute challenge with ﬂumazenil resulted in a signiﬁcant increase of
the percentages of open arm time and entries, as well as decrease of
the time spent in risk assessment, compared to the rats subjected
to withdrawal, but without challenge. Moreover, acute challenge
with ﬂumazenil induced an anxiolytic-like effect close, though not
identical, to that seen with acute administration of diazepam. On
the other hand, some previous reports indicated that ﬂumazenil
may  precipitate a withdrawal syndrome in animals and humans
(File and Hitchcott, 1990; Kaminski et al., 2003; Mintzer et al.,
1999). File and Hitchcott (1990) suggested that such precipitation
of withdrawal with ﬂumazenil may  be expected when tolerance
to the anxiolytic effects of benzodiazepines has not yet developed
and when subsequent anxiogenic response to drug withdrawal on
its own does not ensue. Although the tolerance to the anxiolytic
effect has not been investigated in the present study, the observed
anxiogenic response during withdrawal could be seen as predic-
tive of ﬂumazenil’s anxiolytic effect. Having in mind the data on
adaptive changes at 1GABAA receptors in key brain regions dur-
ing withdrawal (reviewed in Uusi-Oukari and Korpi, 2010), and the
propensity of ﬂumazenil to rapidly reverse the GABA subsensitiv-
ity and the decreased 1-subunit protein expression (Gallager et al.,
1984; Tietz et al., 1999), we hypothesize that the antagonist’s abil-
ity to act through 1GABAA receptors may  be responsible for the
observed anxiolytic-like effect.
In Experiment 2, CCt, a 20-fold selective antagonist at
1GABAA receptors (Cox et al., 1995), was employed to further
investigate the contribution of these receptors to the pro-
cesses underlying the emergence of the increased anxiety during
diazepam withdrawal. The interpretation of the data is critically
dependent on the degree to which the in vitro selectivity of CCt
is reﬂected in vivo. In mice dosed with 30 mg/kg of CCt, the
binding reduction of radiolabeled ﬂumazenil followed the relative
distribution of the 1-subunit, which revealed retained selectiv-
ity of CCt binding (Griebel et al., 1999). Nevertheless, there was
a study in mice suggesting that CCt was  able to antagonize the
anxiolytic-like effects of chlordiazepoxide (Belzung et al., 2000),
which are thought to be dominantly mediated by non-1GABAA
receptors (Smith and Rudolph, 2012). However, chlordiazepoxide
signiﬁcantly increased motor activity in the given experimental
conditions in the EPM (Belzung et al., 2000), and such a ﬁnding
is known to have a potential to confound the data interpreta-
tion, sometimes leading to ‘false positive’ results (Dawson and
Tricklebank, 1995). On the other hand, in an experiment in rats,
CCt failed to antagonize the anxiolytic effect of chlordiazepoxide
(Carroll et al., 2001). This suggests existence of species differences
between rats and mice, which may  contribute to explanation of dis-
crepancies between the reported (Belzung et al., 2000) and present
results and indirectly support that CCt was selective for 1GABAA
receptors in vivo in rats.
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Acute challenge with CCt, 24 h after the last diazepam injec-
ion, led to a signiﬁcant reduction of diazepam withdrawal-induced
nxiety. The inﬂuence of CCt on the anxiety-related parameters
n the EPM was partly affected by the dose administered. Namely,
hile acute challenge with any of the three doses of CCt (1.25, 5
nd 20 mg/kg) signiﬁcantly increased the percentage of open time
ompared to the diazepam-withdrawn group, only administration
f the two higher doses signiﬁcantly increased the percentage of
pen arm entries, whereas only the dose of 20 mg/kg induced a
igniﬁcant decrease in the time spent in risk assessment behavior.
hile the inﬂuence of acute challenge with CCt on anxiety-related
arameters during withdrawal was comparable, with subtle dif-
erences between parameters, to the effects of the non-selective
ntagonist ﬂumazenil, it could be observed that the anxiolytic-
ike effects of acute administration of diazepam tended in both
xperiments to be somewhat more pronounced than after acute
hallenge with two antagonists. On the whole, these data imply
hat GABAA receptors in brain were altered 24 h after termina-
ion of the protracted diazepam treatment, becoming susceptible to
odulation by CCt and ﬂumazenil in a manner akin to the action
f diazepam in experimentally naive rats. This hypothesis could
e connected with ﬁndings of a decrease of 1-containing GABAA
eceptors in certain rodent brain regions, 24 h after diazepam with-
rawal (Impagnatiello et al., 1996).
In summary, the present study conﬁrmed that abrupt ces-
ation of protracted once-daily IP administration of 2 mg/kg
iazepam could induce a withdrawal syndrome in rats, measured
y increased anxiety-like behavior in the EPM paradigm 24 h after
reatment cessation. Additionally, the study provided evidence that
cute challenge with both, a non-selective antagonist ﬂumazenil
nd a preferential 1-subunit selective antagonist CCt, allevi-
tes the diazepam withdrawal-induced anxiety, and even induces
nxiolytic-like response in rats withdrawn from diazepam. These
ndings suggest a common mechanism by which ﬂumazenil and
CCt may  reverse the withdrawal-induced anxiety. In order to fur-
her elucidate the mechanism of alleviation of the benzodiazepine
ithdrawal syndrome, future research should be directed to the
ownstream changes induced by long-term activation and acute
ntagonism at GABAA receptors containing the 1 subunit. Finally,
 closer examination of dose–response relationships with CCt
ould be one of prerequisites needed for possible clinical testing
f this selective antagonist following the withdrawal of benzodi-
zepines.
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